COVID-19 Impact

You may see some delays in posting new content due to COVID-19. If you have any questions, please submit a message to PSNet Support.
 

PSNet: Patient Safety Network
Press Release/Announcement

Nimodipine Capsules (marketed as Nimotop).

Food and Drug Administration; FDA

This U.S. Food and Drug Administration alert reminds health care professionals that nimodipine should only be administered orally, and that intravenous or parenteral administration can cause serious adverse events.